4DMT to Present Interim Data from 4D-150 Phase 1/2 PRISM Clinical Trial for Wet AMD at ARVO 2023, and Promotes Robert Kim, M.D. to Chief Medical Officer
EMERYVILLE, Calif., April 13, 2023 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq:FDMT, 4DMT or the Company), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, today announced an oral presentation of interim data from the 4D-150 Phase 1/2 PRISM clinical trial for wet age-related macular degeneration (wet AMD) at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held April 23-27, 2023 in New Orleans, Louisiana. 4D-150 is designed for single, low-dose intravitreal delivery of a transgene payload that expresses both aflibercept and a VEGF-C inhibitory RNAi and is currently in clinical development for wet AMD and diabetic macular edema (DME).
Related news for (FDMT)
- Closing Bell Heat Check: Biotech Breakouts, Reverse Mergers & Moonshot Setups Heading into After-Hours
- Trade These, Not Those: Capital is Rotating and Here’s Where It’s Headed
- MoBot alert highlights: NASDAQ: CONI, NASDAQ: NAMM, NASDAQ: FDMT, NASDAQ: RAYA, NASDAQ: ADAP (08/01/25 04:00 AM)
- MoBot alert highlights: NASDAQ: MWYN, NASDAQ: NAMM, NASDAQ: IMG, NASDAQ: FDMT, NASDAQ: CETX (07/31/25 07:00 PM)
- MoBot alert highlights: NASDAQ: MWYN, NASDAQ: NAMM, NASDAQ: IMG, NASDAQ: FDMT, NASDAQ: CETX (07/31/25 06:00 PM)